- KRAS mutation and DNA repair and synthesis genes in non‑small‑cell lung cancer
Vienna Ludovini et al, 2018, Molecular and Clinical Oncology CrossRef - Systemic treatments other than TKI: Reflections on chemotherapy, immunotherapy and antiangiogenic agents in ALK-driven NSCLC
Alessandro Leonetti et al, 2021, Therapeutic Strategies to Overcome ALK Resistance in Cancer CrossRef - The impact of fusion genes on cancer stem cells and drug resistance
Saurav Panicker et al, 2021, Molecular and Cellular Biochemistry CrossRef - Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomes
Pascale Tomasini et al, 2016, Therapeutic Advances in Medical Oncology CrossRef - Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer
Jaemin Jo et al, 2018, Yonsei Medical Journal CrossRef - Sustained Improvement in the Management of Patients with Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocation: Where Are We Running?
Gianluca Spitaleri et al, 2023, Current Oncology CrossRef - Prise en charge des patients de stade avancé avec remaniement ALK : aujourd’hui et demain (« qui sera un autre jour... »)
R. Descourt et al, 2017, Revue des Maladies Respiratoires Actualités CrossRef - Simultaneous VENTANA IHC and RT-PCR testing of ALK status in Chinese non-small cell lung cancer patients and response to crizotinib
Chun-wei Xu et al, 2018, Journal of Translational Medicine CrossRef - What is Currently the Best for Adenocarcinoma without Driver Mutation?
Cheol-Kyu Park et al, 2018, Tuberculosis and Respiratory Diseases CrossRef - Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape
K.A. Olaussen et al, 2016, Annals of Oncology CrossRef